N-(3-nitrobenzyl)prop-2-en-1-amine | 893590-94-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: N-(3-nitrobenzyl)prop-2-en-1-amine
• 英文别名: N-allyl-(3-nitrobenzyl)amine；N-[(3-nitrophenyl)methyl]prop-2-en-1-amine
• CAS: 893590-94-8
• 化学式: C₁₀H₁₂N₂O₂
• mdl: MFCD07407735
• 分子量: 192.217
• InChiKey: SRSCWMYGQQRHPY-UHFFFAOYSA-N

物化性质

• 沸点：
  312.8±22.0 °C(Predicted)
• 密度：
  1.123±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  14
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.2
• 拓扑面积：
  57.8
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  N-(3-nitrobenzyl)prop-2-en-1-amine 在 甲醇 、 tin(II) chloride dihdyrate 、 三乙胺 作用下， 以 四氢呋喃 、 二氯甲烷 为溶剂， 反应 1.0h， 生成 N-allyl-N-(3-aminobenzyl)-2,2,2-trifluoroacetamide
  参考文献：
  名称：

  Discovery of Kinase Spectrum Selective Macrocycle (16E)-14-Methyl-20-oxa-5,7,14,26-tetraazatetracyclo[19.3.1.1(2,6).1(8,12)]heptacosa-1(25),2(26),3,5,8(27),9,11,16,21,23-decaene (SB1317/TG02), a Potent Inhibitor of Cyclin Dependent Kinases (CDKs), Janus Kinase 2 (JAK2), and Fms-like Tyrosine Kinase-3 (FLT3) for the Treatment of Cancer

  摘要：

  Herein, we describe the design, synthesis, and SAR of a series of unique small molecule macrocycles that show spectrum selective kinase inhibition of CDKs, JAK2, and FLT3. The most promising leads were assessed in vitro for their inhibition of cancer cell proliferation, solubility, CYP450 inhibition, and microsomal stability. This screening cascade revealed 26h as a preferred compound with target IC50 of 13, 73, and 56 nM for CDK2, JAK2 and FLT3, respectively. Pharmacokinetic (PK) studies of 26h in preclinical species showed good oral exposures. Oral efficacy was observed in colon (HCT-116) and lymphoma (Ramos) xenograft studies, in line with the observed PK/PD correlation. 26h (SB1317/TG02) was progressed into development in 2010 and is currently undergoing phase 1 clinical trials in advanced leukemias and multiple myeloma.

  DOI：

  10.1021/jm201112g
• 作为产物：
  描述：

  1-(3-nitrophenyl)-N-prop-2-enylmethanimine 在 sodium tetrahydroborate 作用下， 以 甲醇 为溶剂， 反应 1.0h， 生成 N-(3-nitrobenzyl)prop-2-en-1-amine
  参考文献：
  名称：

  新型异丙醇胺衍生物作为非肽类人免疫缺陷病毒蛋白酶抑制剂的合成和生物学评估。

  摘要：

  通过结合奈非那韦和安普那韦基序设计了新型潜在的人类免疫缺陷病毒（HIV）蛋白酶抑制剂。通过容易的合成路线制备设计的化合物，并且通过从商业可获得的（S）-2-环氧乙烷基甲基间硝基苯磺酸酯的立体有择合成进一步证实了它们的立体化学。用公开的参考文献19测试了所有化合物抑制HIV 1型蛋白酶活性的能力。在初步生物测定中，衍生物1a-u表现出中等至显着的抑制活性。最好的化合物1a的IC50值为0.02 microM，与氨普那韦相当。使用已发布的HIV 1型蛋白酶的X射线晶体结构对化合物1a-u进行了对接研究，所有化合物都以扩展构象与HIV 1型蛋白酶结合，并且该结合构象的支架可以很好地对齐。进行了比较分子场分析（CoMFA）研究，以探讨静电和空间效应在这些新化合物与HIV 1型蛋白酶结合中的特定作用，并建立了以13种化合物为训练集的预测CoMFA模型。对其他五种化合物作为测试集的测试分析表明，CoM

  DOI：

  10.1248/cpb.56.1147

文献信息

• Carbonylative C−C Bond Activation of Electron-Poor Cyclopropanes: Rhodium-Catalyzed (3+1+2) Cycloadditions of Cyclopropylamides
  作者：Andrew G. Dalling、Takayuki Yamauchi、Niall G. McCreanor、Lydia Cox、John F. Bower

  DOI：10.1002/anie.201811460

  日期：2019.1.2

  Rh‐catalyzed carbonylative C−C bond activation of cyclopropylamides generates configurationally stable rhodacyclopentanones that engage tethered alkenes in (3+1+2) cycloadditions. These studies provide the first examples of multicomponent cycloadditions that proceed through C−C bond activation of “simple” electron poor cyclopropanes.

  环丙基酰胺的Rh催化的羰基C-C键活化生成结构稳定的Rhodacyclopentanones，其与（3 + 1 + 2）环加成中的链状烯烃结合。这些研究提供了多组分环加成反应的第一个例子，该过程通过“简单的”电子贫乏的环丙烷的C-C键活化而进行。
• Macrocyclic compounds as anti-cancer agents: Design and synthesis of multi-acting inhibitors against HDAC, FLT3 and JAK2
  作者：Cheng-Qing Ning、Cheng Lu、Liang Hu、Yan-Jing Bi、Lei Yao、Yu-Jun He、Li-Fei Liu、Xiao-Yu Liu、Nie-Fang Yu

  DOI：10.1016/j.ejmech.2015.03.034

  日期：2015.5

  A novel series of macrocyclic compounds were designed and synthesized as multi-target inhibitors targeting HDAC, FLT3 and JAK2. Some of these compounds exhibited potent HDAC inhibition as well as FLT3 and JAK2 inhibition under both cell-free and cellular conditions. In vitro antiproliferative assay indicated that these compounds were interestingly more cytotoxic to MV4-11 cells bearing FLT3-ITD mutation and HEL cells bearing JAK2(V617F) mutation. (C) 2015 Elsevier Masson SAS. All rights reserved.
• Discovery of Kinase Spectrum Selective Macrocycle (16<i>E</i>)-14-Methyl-20-oxa-5,7,14,26-tetraazatetracyclo[19.3.1.1(2,6).1(8,12)]heptacosa-1(25),2(26),3,5,8(27),9,11,16,21,23-decaene (SB1317/TG02), a Potent Inhibitor of Cyclin Dependent Kinases (CDKs), Janus Kinase 2 (JAK2), and Fms-like Tyrosine Kinase-3 (FLT3) for the Treatment of Cancer
  作者：Anthony D. William、Angeline C.-H. Lee、Kee Chuan Goh、Stéphanie Blanchard、Anders Poulsen、Ee Ling Teo、Harish Nagaraj、Chai Ping Lee、Haishan Wang、Meredith Williams、Eric T. Sun、Changyong Hu、Ramesh Jayaraman、Mohammed Khalid Pasha、Kantharaj Ethirajulu、Jeanette M. Wood、Brian W. Dymock

  DOI：10.1021/jm201112g

  日期：2012.1.12

  Herein, we describe the design, synthesis, and SAR of a series of unique small molecule macrocycles that show spectrum selective kinase inhibition of CDKs, JAK2, and FLT3. The most promising leads were assessed in vitro for their inhibition of cancer cell proliferation, solubility, CYP450 inhibition, and microsomal stability. This screening cascade revealed 26h as a preferred compound with target IC50 of 13, 73, and 56 nM for CDK2, JAK2 and FLT3, respectively. Pharmacokinetic (PK) studies of 26h in preclinical species showed good oral exposures. Oral efficacy was observed in colon (HCT-116) and lymphoma (Ramos) xenograft studies, in line with the observed PK/PD correlation. 26h (SB1317/TG02) was progressed into development in 2010 and is currently undergoing phase 1 clinical trials in advanced leukemias and multiple myeloma.
• Synthesis and Biological Evaluation of Novel Isopropanolamine Derivatives as Non-peptide Human Immunodeficiency Virus Protease Inhibitors
  作者：Lijun Zhou、Qingang Yang、Yong Wang、Youhong Hu、Xiaomin Luo、Donglu Bai、Shukun Li

  DOI：10.1248/cpb.56.1147

  日期：——

  Novel potential human immunodeficiency virus (HIV) protease inhibitors were designed by a combination of nelfinavir and amprenavir motifs. The designed compounds were prepared by a facile synthetic route and their stereochemistry was further confirmed by a stereospecific synthesis from commercially available (S)-2-oxiranylmethyl m-nitrobenzenesulfonate. All compounds were tested for their ability in

  通过结合奈非那韦和安普那韦基序设计了新型潜在的人类免疫缺陷病毒（HIV）蛋白酶抑制剂。通过容易的合成路线制备设计的化合物，并且通过从商业可获得的（S）-2-环氧乙烷基甲基间硝基苯磺酸酯的立体有择合成进一步证实了它们的立体化学。用公开的参考文献19测试了所有化合物抑制HIV 1型蛋白酶活性的能力。在初步生物测定中，衍生物1a-u表现出中等至显着的抑制活性。最好的化合物1a的IC50值为0.02 microM，与氨普那韦相当。使用已发布的HIV 1型蛋白酶的X射线晶体结构对化合物1a-u进行了对接研究，所有化合物都以扩展构象与HIV 1型蛋白酶结合，并且该结合构象的支架可以很好地对齐。进行了比较分子场分析（CoMFA）研究，以探讨静电和空间效应在这些新化合物与HIV 1型蛋白酶结合中的特定作用，并建立了以13种化合物为训练集的预测CoMFA模型。对其他五种化合物作为测试集的测试分析表明，CoM